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Letter to the Editor. 
Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase 
inhibitor-induced growth arrest, apoptosis, and acetylation of histone H3 on p21waf1 
promoter in acute myelogenous leukemia cell 
Histone deacetylase inhibitors (HDACIs) have emerged as a potentially promising new 
class of anticancer drugs.1 These include the hydroxamic acid-derived suberoylanilide 
hydroxamic acid (SAHA, Vorinostat), LBH 589, tricostatin A (TSA), cyclic 
depsipeptide FR901228, and the benzamide MS-275.5 HDACIs induce growth arrest 
and apoptosis of cancer cells by manipulating the transcription of genes involved in 
regulation of the cell cycle and apoptosis, as well as differentiation.1 For example, we 
previously showed that SAHA induces growth arrest and apoptosis of human mantle 
cell lymphoma cells in association with induction of histone acetylation of the p21waf1 
promoter region, resulting in upregulation of the p21waf1 protein.2 
This study found that MS-275 induces growth arrest of human acute myelogenous 
leukemia (AML) HL-60 and NB4 cells, as well as freshly isolated leukemia cells from 
individuals with AML with IC50s values less than 1 μM on day 2 of culture, as 
measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and 
thymidine uptake, respectively (Fig 1a, Table 1). Western blot analyses showed that 
exposure of these cells to MS-275 downregulated levels of antiapoptotic molecules 
Bcl-2 and Mcl-1, and markedly increased levels of p21waf1 in conjunction with induction 
of acetylation of histone H3 proteins (Fig 1b). MS-275 also downregulated levels of 
p-ERK in these cells (Fig 1b). We next explored the drug interaction of MS-275 and 
AZD6244 (ARRY-142886),3 the specific inhibitor of MEK/ERK activity, in AML cells. 
Interestingly, AZD6244 synergistically potentiated MS-275-induced growth arrest and 
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apoptosis of these cells in association with enhanced induction of p21waf1 
(Supplementary Figs 1a-e). We further explored the molecular mechanisms by which 
blockade of MEK/ERK signaling enhanced MS-275-induced expression of p21waf1; 
AZD6244 increased MS-275-induced acetylation of histone H3 proteins in AML cells 
(Fig 2a). Of note, chromatin immunoprecipitation assay found that combination of 
AZD6244 and MS-275 synergistically induced acetylation of histone H3 on the p21waf1 
promoter in AML cells (Fig 2b). Moreover, MS-275 or AZD6244 either alone modestly 
downregulated levels of p-histone H3 and combination of both at the same 
concentration further downregulated levels of p-histone H3 in these cells 
(Supplementary Fig 2). This is the first observation that blockade of MEK/ERK 
signaling modulates the epigenetic action of HDACI. Phosphorylation of histone H3 
coincided with chromatin condensation in mitosis in eukaryotic cells.4,5 Inhibition of 
p-histone H3 by this MEK inhibitor may cause chromatin relaxation, leading to 
susceptibility to HDACI-induced acetylation of the gene promoter. 
A recent phase I clinical trial has evaluated efficacy and safety of MS-275 in 38 
individuals with relapsed or refractory AML. MS-275 induced acetylation of histone 
H3/H4, expression of p21waf1 and activation of caspase 3 in bone marrow mononuclear 
cells, although no responses were observed by classical criteria.6  
Taken together, combination of MS-275 and AD6244 may be useful for treatment of 
individuals with AML. Further studies are required to verify the molecular mechanisms 
by which blockade of MEK/ERK signaling affects chromatin remodeling. 
 
Supplementary information accompanies the paper on the Leukemia website 
(http://www.nature.com/leu). 
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Figure Legends 
Fig 1. (a), Antiproliferative effects of MS-275 against leukemia cells. The human 
leukemia HL60 and NB4 cells were plated in 96-well plates and cultured with various 
concentrations of MS-275 (0.1-6 μM). After 2 days, cell proliferation was measured by 
MTT assay. Results represent the mean ± SD of three experiments performed in 
triplicate. (b), MS-275 modulates levels of antiapoptotic and cell cycle related 
proteins and induces acetylation of histone H3. Western blot analysis. HL60 and 
NB4 cells were cultured with various concentrations of MS-275 (0.25-1 μM). After 48 
hours, cells were harvested and subjected to Western blot analysis. The membranes were 
sequentially probed with the indicated antibodies. The figures represent one of the three 
experiments performed independently. Ac-histone H3, acetylated-histone H3.  
 
Fig 2. AZD6244 enhanced MS-275-induced acetylation of histone H3. (a) Western 
blot analysis. HL60 and NB4 cells were cultured in the presence of either MS-275 (0.5 
μM) and/or AZD6244 (0.25 μM). After 6 hours, cells were harvested and nuclear 
proteins were prepared and subjected to Western blot analysis. The membranes were 
sequentially probed with anti-acetyl-histone H3 and anti-α-tubulin antibodies. The 
figure is representative of three similar experiments. Ac-histone H3, acetylated-histone 
H3. (b) Chromatin immunoprecipitation assay. Acetylation of histone H3 in the 
p21waf1 promoter was analyzed by chromatin immunoprecipitation assay. HL60 and 
NB4 cells were cultured in the presence of either MS-275 (0.5 μM) and/or AZD6244 
(0.25 μM). After 6 hours, cells were harvested and subjected to chromatin 
immunoprecipitation assay. Anti-acetylated histone H3 antibody or rabbit IgG was used 
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to immunoprecipitate soluble chromatin from these cells. The recovered DNAs were 
subjected to PCR using primers for p21waf1promoter. The band intensity was measured 
by densitometry. The result is representative of two additional experiments performed 
independently.  
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Table 1. Effect of MS-275 on freshly isolated acute leukemia cells 
 
Pt. # Age/Sex FAB WBC x109 % Blast Genetic abnormalities Source  IC50  Previous Treatment 
1 67/M M2 38,700 54% t(8;21)(q22;q22)  PB 0.05 No 
2 57/M M3 1,100 40% t(15;17)(q22;q12) BM 0.3 No 
3 63/M M4 79,400 69% normal  PB 0.1 No 
4 79/F M4 34,200 50% normal  PB 0.06 No 
5 77/F M7 2,000 38% complex  PB 1 Yes 
6 50/F M3 6,300 89% t(15;17)(q22;q12)  BM 0.06 No          
The freshly isolated leukemia cells were cultured in the presence of various concentrations of MS-275 (0.03–1 μM).  
After 2 days, cell proliferation was measured by tritiated thymidine uptake. The results were graphed and the concentration of MS-275 
that induced 50% inhibition (IC50) of thymidine-uptake was calculated from the dose-response curves. 
BM, bone marrow; F, female; FAB, French−American-British (leukemia classification); M, male; PB, peripheral blood; Pt, patient; 
WBC, white blood cell. 
 
 
 
